Circulating Serum Exosomal MiRNAs As Potential Biomarkers for Esophageal Adenocarcinoma

Overview

Journal J Gastrointest Surg

Specialty Gastroenterology

Date 2015 May 7

PMID 25943911

Citations 77

Authors

Karen Chiam

Tingting Wang

David I Watson

George C Mayne

Tanya S Irvine

Tim Bright

Lorelle Smith

Imogen A White

Joanne M Bowen

Dorothy Keefe

Sarah K Thompson

Michael E Jones

Damian J Hussey

Affiliations

Soon will be listed here.

Abstract

Background: The poor prognosis and rising incidence of esophageal adenocarcinoma highlight the need for improved detection methods. The potential for circulating microRNAs (miRNAs) as biomarkers in other cancers has been shown, but circulating miRNAs have not been well characterized in esophageal adenocarcinoma. We investigated whether circulating exosomal miRNAs have potential to discriminate individuals with esophageal adenocarcinoma from healthy controls and non-dysplastic Barrett's esophagus.

Methods: Seven hundred fifty-eight miRNAs were profiled in serum circulating exosomes from a cohort of 19 healthy controls, 10 individuals with Barrett's esophagus, and 18 individuals with locally advanced esophageal adenocarcinoma. MiRNA expression was assessed using all possible permutations of miRNA ratios per individual. Four hundred eight miRNA ratios were differentially expressed in individuals with cancer compared to controls and Barrett's esophagus (Mann-Whitney U test, P < 0.05). The 179/408 ratios discriminated esophageal adenocarcinoma from healthy controls and Barrett's esophagus (linear regression, P < 0.05; area under receiver operating characteristic (ROC) > 0.7, P < 0.05). A multi-biomarker panel (RNU6-1/miR-16-5p, miR-25-3p/miR-320a, let-7e-5p/miR-15b-5p, miR-30a-5p/miR-324-5p, miR-17-5p/miR-194-5p) demonstrated enhanced specificity and sensitivity (area under ROC = 0.99, 95% CI 0.96-1.0) over single miRNA ratios to distinguish esophageal adenocarcinoma from controls and Barrett's esophagus.

Conclusions: This study highlights the potential for serum exosomal miRNAs as biomarkers for the detection of esophageal adenocarcinoma.

Citing Articles

Enhanced packaging of U6 small nuclear RNA and splicing-related proteins into extracellular vesicles during HIV infection.

Huang Y, Abdelgawad A, Gololobova O, Liao Z, Cong X, Batish M Sci Adv. 2025; 11(11):eadq6557.

PMID: 40073117 PMC: 11900857. DOI: 10.1126/sciadv.adq6557.

Exosomes in esophageal cancer: function and therapeutic prospects.

Wang C, Shi Z Med Oncol. 2024; 42(1):18.

PMID: 39601925 DOI: 10.1007/s12032-024-02543-x.

Latest insights into the global epidemiological features, screening, early diagnosis and prognosis prediction of esophageal squamous cell carcinoma.

Zhao Y, Zhao H, Zhao M, Yu Y, Qi X, Wang J World J Gastroenterol. 2024; 30(20):2638-2656.

PMID: 38855150 PMC: 11154680. DOI: 10.3748/wjg.v30.i20.2638.

The Circulating Biomarkers League: Combining miRNAs with Cell-Free DNAs and Proteins.

Felekkis K, Papaneophytou C Int J Mol Sci. 2024; 25(6).

PMID: 38542382 PMC: 10969827. DOI: 10.3390/ijms25063403.

Advances in Screening for Barrett Esophagus and Esophageal Adenocarcinoma.

Vantanasiri K, Kamboj A, Kisiel J, Iyer P Mayo Clin Proc. 2024; 99(3):459-473.

PMID: 38276943 PMC: 10922282. DOI: 10.1016/j.mayocp.2023.07.014.

References

Appaiah H, Goswami C, Mina L, Badve S, Sledge Jr G, Liu Y . Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Res. 2011; 13(5):R86. PMC: 3262198. DOI: 10.1186/bcr2943. View

Wijnhoven B, Hussey D, Watson D, Tsykin A, Smith C, Z Michael M . MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surg. 2010; 97(6):853-61. DOI: 10.1002/bjs.7000. View

Koberle V, Pleli T, Schmithals C, Augusto Alonso E, Haupenthal J, Bonig H . Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. PLoS One. 2013; 8(9):e75184. PMC: 3779196. DOI: 10.1371/journal.pone.0075184. View

Warnecke-Eberz U, Chon S, Holscher A, Drebber U, Bollschweiler E . Exosomal onco-miRs from serum of patients with adenocarcinoma of the esophagus: comparison of miRNA profiles of exosomes and matching tumor. Tumour Biol. 2015; 36(6):4643-53. DOI: 10.1007/s13277-015-3112-0. View

Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F . MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011; 108(9):3713-8. PMC: 3048155. DOI: 10.1073/pnas.1100048108. View

Tanaka Y, Kamohara H, Kinoshita K, Kurashige J, Ishimoto T, Iwatsuki M . Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer. 2012; 119(6):1159-67. DOI: 10.1002/cncr.27895. View

Gordon L, Mayne G, Hirst N, Bright T, Whiteman D, Watson D . Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett's esophagus. Gastrointest Endosc. 2013; 79(2):242-56.e6. DOI: 10.1016/j.gie.2013.07.046. View

Wang X, Cao L, Wang Y, Wang X, Liu N, You Y . Regulation of let-7 and its target oncogenes (Review). Oncol Lett. 2012; 3(5):955-960. PMC: 3389667. DOI: 10.3892/ol.2012.609. View

Sayed D, Abdellatif M . MicroRNAs in development and disease. Physiol Rev. 2011; 91(3):827-87. DOI: 10.1152/physrev.00006.2010. View

10.

Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F . Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol. 2014; 32(8):768-73. PMC: 4876348. DOI: 10.1200/JCO.2013.50.4357. View

11.

Dubecz A, Solymosi N, Stadlhuber R, Schweigert M, Stein H, Peters J . Does the Incidence of Adenocarcinoma of the Esophagus and Gastric Cardia Continue to Rise in the Twenty-First Century?—a SEER Database Analysis. J Gastrointest Surg. 2013; 18(1):124-129. DOI: 10.1007/s11605-013-2345-8. View

12.

Moldovan L, Batte K, Trgovcich J, Wisler J, Marsh C, Piper M . Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med. 2014; 18(3):371-90. PMC: 3943687. DOI: 10.1111/jcmm.12236. View

13.

Manterola L, Guruceaga E, Gallego Perez-Larraya J, Gonzalez-Huarriz M, Jauregui P, Tejada S . A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol. 2014; 16(4):520-7. PMC: 3956347. DOI: 10.1093/neuonc/not218. View

14.

Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K . Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One. 2014; 9(4):e92921. PMC: 3976275. DOI: 10.1371/journal.pone.0092921. View

15.

Li Z, Ying X, Chen H, Ye P, Shen Y, Pan W . MicroRNA-194 inhibits the epithelial-mesenchymal transition in gastric cancer cells by targeting FoxM1. Dig Dis Sci. 2014; 59(9):2145-52. DOI: 10.1007/s10620-014-3159-6. View

16.

Bansal A, Lee I, Hong X, Anand V, Mathur S, Gaddam S . Feasibility of mcroRNAs as biomarkers for Barrett's Esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol. 2011; 106(6):1055-63. DOI: 10.1038/ajg.2011.37. View

17.

Wu X, Ajani J, Gu J, Chang D, Tan W, Hildebrandt M . MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila). 2013; 6(3):196-205. PMC: 3608471. DOI: 10.1158/1940-6207.CAPR-12-0276. View

18.

Mogilyansky E, Rigoutsos I . The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013; 20(12):1603-14. PMC: 3824591. DOI: 10.1038/cdd.2013.125. View

19.

Wang J, Zhang K, Liu S, Sen S . Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules. 2014; 19(2):1912-38. PMC: 6271223. DOI: 10.3390/molecules19021912. View

20.

Zingg U, Smithers B, Gotley D, Smith G, Aly A, Clough A . Factors associated with postoperative pulmonary morbidity after esophagectomy for cancer. Ann Surg Oncol. 2010; 18(5):1460-8. DOI: 10.1245/s10434-010-1474-5. View